Hajdúch Marián M.D., Ph.D.
Academic title:
Associate Professor
E-mail:
marian.hajduch@upol.cz
Phone:
+420 585632082, +420 585632083
Groups:
IMTM, LEM, STAFF, SUPERVISOR
About me
Scientist and medical professional mainly involved in molecular and translational medicine (disease area oncology. rare and infectious diseases); long-term experience in project management; R&D and technology transfer activities, including the construction and management of large research infrastructures. Founding director of the Institute of Molecular and Translational Medicine, Palacky University in Olomouc, CZ. He has been involved as principal investigator, investigator or clinical site manager in 19 clinical trials; actively participated in the research and/or management of >50 national and international projects; established Cancer Research Czech Republic as a major charity to support cancer research in CZ; spin-off companies focused on manufacturing of molecular diagnostics, bioinformatics and drug development; leader/co-leader drug development initiatives with one registered drug on market, several products in clinical trials, >35 in vitro diagnostic products on market, several CE IVD certified. Former Chair of the Boards of National Director and current Czech National Director for European Translational Medicine Infrastructure (EATRIS-ERIC); participated in creation of national network for personalized medicine and cancer management policies. Published more than >350 papers, 21 books/chapters, >40 patents, >6700 SCI citations, H-index 41.
Journals
IDH1/2 Mutations in Patients With Diffuse Gliomas.
Applied Immunohistochemistry and Molecular Morphology.
2021,
30(3),
178-183,
ISSN: 1541-2016,
PMID: 35262523,
2‑Cl‑IB‑MECA regulates the proliferative and drug resistance pathways, and facilitates chemosensitivity in pancreatic and liver cancer cell lines.
International Journal of Molecular Medicine.
2022,
49(3),
31,
ISSN: 1107-3756,
PMID: 35039871,
Open positions
| Project: | Identification of proteomic biomarkers in exhaled air condensate in patients with systemic or pulmonary disease |
|---|---|
| Supervisors: | Džubák Petr M.D., Ph.D., Hajdúch Marián M.D., Ph.D. |
| Available: | 2 |
| Intended for: | Doctoral training |
| Summary: | 2 places in full-time study |
| Project: | Antitumor drugs targeting nucleic acid metabolism |
|---|---|
| Supervisors: | Džubák Petr M.D., Ph.D., Hajdúch Marián M.D., Ph.D. |
| Available: | 2 |
| Intended for: | Doctoral training |
| Summary: | 2 places in full-time study |
| Project: | Bioinformatics processing of big data within clinical and preclinical studies |
|---|---|
| Supervisors: | Hajdúch Marián M.D., Ph.D., Pavliš Petr Ph.D. |
| Available: | 3 |
| Intended for: | Doctoral training |
| Summary: | 3 places in full-time or combined form of study |
| Project: | Identification of molecular targets and mechanisms of resistance in antitumor drugs using cell biology and proteomics methods |
|---|---|
| Supervisors: | Džubák Petr M.D., Ph.D., Hajdúch Marián M.D., Ph.D. |
| Available: | 2 |
| Intended for: | Doctoral training |
| Summary: | 2 places in full-time study |
| Project: | Physiology and pathophysiology of aging |
|---|---|
| Supervisors: | Hajdúch Marián M.D., Ph.D., Voller Jiří Ph.D. |
| Available: | 2 |
| Intended for: | Doctoral training |
| Summary: | 2 places in full-time study |
| Project: | Drug repurposing for treatment and prevention of diseases |
|---|---|
| Supervisors: | Hajdúch Marián M.D., Ph.D. |
| Available: | 1 |
| Intended for: | Doctoral training |
| Summary: | 1 place in full-time study |
| Project: | Drug development of small molecules |
|---|---|
| Supervisors: | Hajdúch Marián M.D., Ph.D. |
| Available: | 2 |
| Intended for: | Doctoral training |
| Summary: | 2 places in full-time study |
| Project: | Diagnostics and therapy of rare diseases |
|---|---|
| Supervisors: | Hajdúch Marián M.D., Ph.D., Srovnal Josef M.D., Ph.D. |
| Available: | 2 |
| Intended for: | Doctoral training |
| Summary: | 2 places in full-time study |
| Project: | New prognostic and predictive factors in solid tumors |
|---|---|
| Supervisors: | Hajdúch Marián M.D., Ph.D., Srovnal Josef M.D., Ph.D. |
| Available: | 3 |
| Intended for: | Doctoral training |
| Summary: | 3 places in full-time or combined form of study |
| Project: | Genetic and epigenetic biomarkers of cancer diseases |
|---|---|
| Supervisors: | Slavkovský Rastislav Ph.D., Džubák Petr M.D., Ph.D., Hajdúch Marián M.D., Ph.D. |
| Available: | 3 |
| Intended for: | Doctoral training |
| Summary: | 3 places in full-time study |
| Project: | Genetic and epigenetic biomarkers in cancer |
|---|---|
| Supervisors: | Drábek Jiří Ph.D., Slavkovský Rastislav Ph.D., Hajdúch Marián M.D., Ph.D. |
| Available: | 3 |
| Intended for: | Doctoral training |
| Summary: | Clonal hematopoiesis of indeterminate potential (CHIP) has recently been described as a common phenomenon associated with aging. It is characterized by the accumulation of somatic mutations in cells of the hematopoietic system. Although CHIP is manifested by the expansion of certain cell clones, this condition is not accompanied by any morphological features of hematological neoplasia. However, it has been shown that the incidence of clonal hematopoiesis correlates with increased overall mortality and the risk of developing malignant transformation of hematopoietic cells as well as cardiovascular disease, such as ischemic stroke. To what extent and by what mechanisms clonal hematopoiesis contributes to disease development remains a question of current research. The main aim of the project will be to pinpoint the principal cells carrying CHIP somatic mutations, and to study their role in development and maintenance of atherosclerotic plaques, especially of those involved in development of stroke. The comparison of the phenotype of CHIP positive and negative cells will be of special interest. The use of cellular models not only include different types of leucocytes but circulatory progenitor endothelial cells as well. The study will involve elderly subjects with the positive presence of CHIP (>65 years). Subject will be characterized based on the presence or absence of ischemic stroke and the presence or absence of carotid stenosis by our clinical collaborators. The presence of somatic variants in 38 selected genes associated with CHIP will be tested in subjects of interest within our research group. The project will use various techiques including FACS, MACS, cell cultures, DNA isolation from small amount of cells, a highly sensitive sequencing method for DNA genotyping allowing detection of variant with less than 1% allelic frequency, DNA/RNA sequencing library preparation, deep massively parallel sequencing of panel of genes using unique molecular barcodes/indices, RNAseq, bioinformatics and data analysis with possibilities of calculations using high performance computing cluster, data management and statistical evaluation. |
| Project: | Identification of proteomic biomarkers in exhaled breath condensate in patients with systemic or pulmonary disease |
|---|---|
| Supervisors: | Džubák Petr M.D., Ph.D., Hajdúch Marián M.D., Ph.D. |
| Available: | 2 |
| Intended for: | Doctoral training |
| Summary: | Ph.D. topic is focused on the identification of biomarkers of lung diseases by means of a non-invasive collection of exhaled breath condensate. The project will monitor the presence of proteins in exhaled air in various diseases such as asthma, cystic fibrosis, lung tumors, or some infectious diseases, as well as quantitative changes of these proteins compared to a healthy population. Changes in these potential biomarkers with respect to therapeutic response and disease progression will be evaluated and validated. |
| Project: | Identification of novel proteomic cancer biomarkers |
|---|---|
| Supervisors: | Hajdúch Marián M.D., Ph.D. |
| Available: | 2 |
| Intended for: | Doctoral training |
| Project: | New prognostic and predictive factors in solid tumors |
|---|---|
| Supervisors: | Srovnal Josef M.D., Ph.D., Hajdúch Marián M.D., Ph.D. |
| Available: | 2 |
| Intended for: | Doctoral training |
| Summary: | Cancer is the second leading cause of death in the western countries. Early diagnosis and targeted therapy improve the therapeutic outcome. With the emergence of new biotechnologies, diagnosis can be made early and precisely, and the knowledge of tumor molecular genetics can identify the most appropriate therapy for a particular patient. The sensitivity of modern molecular methods makes it possible to characterize the tumor properties from sites remote from the primary tumor using patient's blood. The subject of the offered study program is the identification of new prognostic and predictive biomarkers of cancer using liquid biopsies. This is particularly the analysis of circulating tumor cells (CTCs), circulating free tumor DNA (ctDNA) and circulating miRNAs. The aim of the project is to further implement a liquid biopsy concept into the diagnosis and therapy monitoring of solid tumors, especially colorectal, breast, lung and CNS tumors. These include therapy response and resistance monitoring, identifying new therapeutic targets and estimating disease prognosis. The project will provide training in widely-used, transferable techniques, including circulation tumor cells capture system, digital droplet PCR, reverse-transcription qPCR, RNA-seq, single cell analyses, xenografts models and other multi-omics methods. We are looking for candidates with a background in Molecular Biology, Medicine, Cell Biology or a related area, who are enthusiastic about investigating novel approaches in cancer diagnostic that have significant potential for public health. |
| Project: | Pharmacokinetic methods in preclinical drug testing |
|---|---|
| Supervisors: | Hajdúch Marián M.D., Ph.D., Lišková Barbora Ph.D. |
| Available: | 1 |
| Intended for: | Doctoral training |
| Summary: | The study of ADME properties of a potential drug that are part of the IMTM chemical library - obtained by national or international cooperation belongs to one of the first steps in predicting potential drugs. In vitro models generate many ADME parameters, including chemical, plasma and microsomal stability, plasma protein binding and proportion of passive diffusion as a transport mechanism. The Caco-2 and MDCK-MDR1 permeability assays are established models of intestinal and blood-brain barriers, respectively. Analysis of samples is performed using a Agilent RapidFire 300 - rapid online solid phase extraction with subsequent detection of the mass spectrometer Qtrap 5500 (AB Sciex) - RF/MS. High-Throughput Mass Spectrometry System RF/MS delivers ultrafast, label – free analysis of native compounds for biochemical assays in ADME and provide throughput speeds of 6 to 10 seconds per sample. |
| Project: | Identification of molecular targets of anticancer therapy applying cell biology and proteomics tools |
|---|---|
| Supervisors: | Džubák Petr M.D., Ph.D., Hajdúch Marián M.D., Ph.D. |
| Available: | 2 |
| Intended for: | Doctoral training |
| Summary: | Selected, highly active derivatives of triterpenes, chelators and nucleosides will be studied with a view to identify the mechanisms of their antitumor effects. Advanced methods of cell biology, proteomics and genomics such as affinity purification of protein targets, CETSA and others will be used for their study. The identified targets will be validated in relation to their clinical relevance in anticancer therapy. |
| Project: | Drug resistance mechanisms in cancer |
|---|---|
| Supervisors: | Džubák Petr M.D., Ph.D., Hajdúch Marián M.D., Ph.D. |
| Available: | 2 |
| Intended for: | Doctoral training |
| Summary: | Mechanisms of tumor cell resistance to newly developed and existing nucleoside analog cytostatics will be studied. These drugs are used in most anti-cancer therapy protocols and the emergence of drug resistance is a major problem in the treatment of cancer patients. Resistant cell lines prepared in the past will be studied to identify the key mechanisms of resistance, which will be carried out by their detailed characterization using cell biology, but also proteomics and molecular genetics. The significance of the identified changes will be further verified on clinical material and will be applied in the development of new anticancer drugs from this class. |
| Project: | Biology of aging and DNA damage |
|---|---|
| Supervisors: | Hajdúch Marián M.D., Ph.D. |
| Available: | 1 |
| Intended for: | Doctoral training |
| Project: | Pathological conditions associated with human papillomavirus infection |
|---|---|
| Supervisors: | Koudeláková Vladimíra Ph.D., Hajdúch Marián M.D., Ph.D. |
| Available: | 2 |
| Intended for: | Doctoral training |
| Summary: | High-risk human papillomavirus infection (HPV infection) is associated with several cancers such as cervical, vaginal, vulvar, head and neck, anal, and penile carcinomas. Nearly all cervical cancers are caused by HPV infection. Despite available vaccination and cervical cancer screening program, cervical cancer is one of the most common types of cancer affecting women worldwide. Main problems of cervical cancer screening are low participation rate and low sensitivity of cytology which is still used in the majority of cervical cancer screening programs. Solution could be the transition to primary HPV screening and the sending of self-sampling devices to cervical cancer screening non-attenders. The best strategy for enrolling Czech women in the screening program will be analysed during this project. Obtained samples will be tested for the presence of HPV DNA and the presence of other molecular biomarkers important in viral clearance and cervical cancer progression/regression. Discoveries will lead to identification of biomarkers for early diagnosis, disease progression or triage strategies. The aim of the project is to clarify the best strategy for enrolling women who do not attend cervical cancer screening program. The second aim is to study genetic and proteomic profile of HPV positive/negative women with normal/abnormal cervical cytology as well as genetic variants of HPV and its importance for regression/progression of the disease. Skills to be taught include biochemistry, molecular biology, bioinformatics and cell culture. This is an ideal project for a student who wishes to pursue higher studies in cancer research. The project will use various techniques including PCR, in situ hybridization, next generation sequencing, mass spectrometry. |
| Project: | Identification of molecular targets and resistance mechanisms of anticancer drugs by cell biology and proteomics methods |
|---|---|
| Supervisors: | Hajdúch Marián M.D., Ph.D., Džubák Petr M.D., Ph.D. |
| Available: | 2 |
| Intended for: | Doctoral training |
| Project: | Identification of proteomic biomarkers in exhaled breath condensate patients with systemic or pulmonary disease |
|---|---|
| Supervisors: | Džubák Petr M.D., Ph.D., Hajdúch Marián M.D., Ph.D. |
| Available: | 2 |
| Intended for: | Doctoral training |
| Project: | Bioinformatics processing of big data in clinical and preclinical studies |
|---|---|
| Supervisors: | Hajdúch Marián M.D., Ph.D., Pavliš Petr Ph.D., Vrbková Jana Ph.D. |
| Available: | 3 |
| Intended for: | Doctoral training |
| Project: | Drug repurposing for treatment and prevention of diseases |
|---|---|
| Supervisors: | Hajdúch Marián M.D., Ph.D., Gurská Soňa Ph.D. |
| Available: | 2 |
| Intended for: | Doctoral training |
| Project: | Biologically active molecules and their therapeutic combinations |
|---|---|
| Supervisors: | Hajdúch Marián M.D., Ph.D. |
| Available: | 2 |
| Intended for: | Doctoral training |
| Project: | Anticancer drugs targeting nucleic acid metabolism |
|---|---|
| Supervisors: | Hajdúch Marián M.D., Ph.D., Džubák Petr M.D., Ph.D. |
| Available: | 2 |
| Intended for: | Doctoral training |
| Project: | Synthesis and characterization of 2D nanoplatforms as active drug carriers |
|---|---|
| Supervisors: | Ranc Václav Ph.D., Hajdúch Marián M.D., Ph.D. |
| Available: | 3 |
| Intended for: | Doctoral training |
| Project: | Physiology and pathophysiology of ageing |
|---|---|
| Supervisors: | Hajdúch Marián M.D., Ph.D., Voller Jiří Ph.D. |
| Available: | 2 |
| Intended for: | Doctoral training |
| Project: | Identification of proteomic biomarkers in proximal fluids and tissues |
|---|---|
| Supervisors: | Džubák Petr M.D., Ph.D., Hajdúch Marián M.D., Ph.D. |
| Available: | 2 |
| Intended for: | Doctoral training |
| Project: | Diagnosis and treatment of rare diseases |
|---|---|
| Supervisors: | Hajdúch Marián M.D., Ph.D., Srovnal Josef M.D., Ph.D. |
| Available: | 2 |
| Intended for: | Doctoral training |
| Project: | New methods in protein degradation |
|---|---|
| Supervisors: | Holub Dušan Ph.D., Hajdúch Marián M.D., Ph.D. |
| Available: | 2 |
| Intended for: | Doctoral training |
| Project: | Research and development of agents for cancer, neurodegenerative and infectious diseases |
|---|---|
| Supervisors: | De Sanctis Juan Bautista Ph.D., Hajdúch Marián M.D., Ph.D., Džubák Petr M.D., Ph.D., Urban Milan Ph.D., Das Viswanath M.Sc., Ph.D. |
| Available: | 5 |
| Intended for: | Doctoral training |
| Project: | New prognostic and predictive factors in solid tumors |
|---|---|
| Supervisors: | Hajdúch Marián M.D., Ph.D., Srovnal Josef M.D., Ph.D., Koudeláková Vladimíra Ph.D. |
| Available: | 3 |
| Intended for: | Doctoral training |
| Project: | Genetic and epigenetic biomarkers in health and disease |
|---|---|
| Supervisors: | Slavkovský Rastislav Ph.D., Džubák Petr M.D., Ph.D., Hajdúch Marián M.D., Ph.D., Drábek Jiří Ph.D., Koudeláková Vladimíra Ph.D. |
| Available: | 5 |
| Intended for: | Doctoral training |